natgillin/translations-raw huggingface dataset:
increased sensitivity to light floating spots before the eyes
večja občutljivost za svetlobo plavajoče pike pred očmi
increased sensitivity to light, appearance of flashing lights
večja občutljivost za svetlobo, bliskanje pred očmi
increased sensitivity to pain
povečana občutljivost na bolečino
increased sensitivity to the sun causing skin rash
povečana občutljivost na sončno svetlobo z kožnim izpuščajem
Increased serum glutamic pyruvic transaminase activity also occurred in one of four dogs.
Pri enem od štirih psov so ugotovili tudi povečano aktivnost serumske glutamat-piruvat-transaminaze.
increased sex drive
povečana spolna želja
increased sex drive
povečana spolna želja,
increased sex drive
povečana spolna željazmedenost
increased sex drive
povečano spolno poželenje
Increased sexual desire
povečanje spolne sle,
Increased side effects may occur in case of recent or concomitant use of hepatotoxicor haematotoxic drugs or when leflunomide treatment is followed by such drugs without a washout period (see also guidance concerning combination with other treatments, section 4.4).
Če se leflunomid uporabi sočasno s hepatotoksičnimi ali hematotoksičnimi zdravili ali če zdravljenju z leflunomidom sledi zdravljenje s takšnimi zdravili brez obdobja izpiranja, se lahko neželeni učinki stopnjujejo (glejte tudi smernice glede kombiniranja z drugimi zdravili, poglavje 4.4).
Increased simeprevir concentrations may occur
pravastatina in uporabljajte
increased skin sensitivity
povečana občutljivost kože
increased skin sensitivity (especially to hot and cold)
zvečana občutljivost kože (zlasti za vročino in mraz);
increased skin sensitivity to sunlight
povečana občutljivost kože na sončno svetlobo,
increased skin sensitivity to sunlight
večja občutljivost kože za sončno svetlobo,
increased skin sensitivity, skin pain
povečana občutljivost kože, boleča koža
increased sodium or magnesium, ketones in the blood and urine (ketoacidosis), renal function tests abnormal, kidney failure
povišana koncentracija natrija ali magnezija, ketonov v krvi in seču (ketoacidoza), neobičajni rezultati testov delovanja ledvic, ledvična odpoved
Increased spleen size and cases of spleen ruptures have been reported.
Poročali so tudi o redkih primerih zvečanja vranice in rupturah (pretrganju) vranice.
Increased spleen size and very rare cases (likely to occur in fewer than 1 in 10,000 patients)) of spleen rupture have been reported after the use of Neupopeg.
Poročali so o povečani vranici in zelo redko ((verjetno je, da se bodo pojavile pri manj kot 1 od 10.000 bolnikov) o primerih rupture vranice po uporabi Neupopega.
Increased spleen size has been reported uncommonly (may affect up to 1 in 100 people) and cases of splenic ruptures have been reported with other medicines similar to Lonquex.
Pri uporabi drugih zdravil, ki so podobna zdravilu Lonquex, so občasno (pojavi se lahko pri največ 1 od 100 bolnikov) poročali o povečanju velikosti vranice in raztrganjih vranice.
increased spontaneous bleeding in patients with haemophilia, anemia including acute haemolytic anaemia, thrombocytopenia (see section 4.4).
povečanje pojava spontanih krvavitev pri bolnikih s hemofilijo, anemija vključno z akutno hemolitično anemijo, trombocitopenija (glejte poglavje 4.4).
increased sugar in blood
povečana koncentracija sladkorja v krvi
increased sugar in the blood
zvišan sladkor v krvi,
increased sugar in the blood, loss of weight
povečana koncentracija sladkorja v krvi, hujšanje
increased sugar level (shown in blood tests) increased liver pigment (called “bilirubin”) in the blood.
zvišana koncentracija sladkorja (pokaže se na preiskavah krvi), porast jetrnega barvila (imenovanega "bilirubin") v krvi.
increased sugar, fatty acids (triglycerides), bilirubin in your blood
povišanje količine sladkorja, maščobnih kislin (trigliceridi), bilirubina v krvi
increased susceptibility to infection
povečana občutljivost za okužbo
Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression (see section 4.8).
Imunosupresija lahko povzroči zvečano dovzetnost za okužbo in možen razvoj limfoma in drugih malignih bolezni, posebno kožnih (glejte poglavje 4.8).
Increased sweating
močnejše znojenje,
increased sweating
obilnejše potenje
Increased sweating
povečano potenje
increased sweating
povečano potenje,
increased sweating
povečano znojenje
increased sweating
povečano znojenje,
Increased sweating
zvečano znojenje,
increased sweating
čezmerno znojenje,
increased sweating hardness, redness, swelling or bruising at the injection site
povečano potenje, otrdlina, rdečina, oteklina ali podplutba na mestu injiciranja.
increased sweating weakness, shivering
povečano znojenje šibkost, drgetanje
increased sweating,
močnejše znojenje,
increased sweating,
povečano potenje,
increased sweating, (itchy) rash
povečano znojenje, (srbeč) izpuščaj
increased sweating, (itchy) rash;
povečano znojenje, (srbeč) izpuščaj;
Increased sweating, night sweats
povečano znojenje, nočno znojenje,
increased sweating, rashes
močnejše potenje, izpuščaj
increased sweating, rashes
močnejše potenje, srbenje in izpuščaj
Increased sweating.
Povečano znojenje.
Increased sweating.
zvečano potenje,
Increased sweating.
zvečano znojenje
Increased sweating.
zvečano znojenje,
increased sweating;
povečano potenje;
increased sweating; hair loss; itching; dry skin; oily skin
povečano potenje, izpadanje las, srbenje, suha koža, mastna koža
increased tear production
močnejše solzenje
increased tearing
povečano solzenje
increased temperature, hot flushes
povišana telesna temperatura, vročinski oblivi
Increased tendency to bruise
večja nagnjenost k modricam
Increased tendency to bruise
večja nagnjenost k podplutbam
Increased tendency to bruise Hot flush
večja nagnjenost k modricam
increased tendency to bruise, dry skin, psoriasis, skin redness, excessive sweating
hitrejši pojav modric, suha koža, luskavica, rdečina kože, čezmerno znojenje,
increased tiredness
povečana utrujenost
increased to 400 mg twice daily
efavirenza pa zmanjšati za 50 %, to
increased to 600 mg twice daily
enkrat na dan
Increased total
Zvišan celokupni bilirubin
Increased total bilirubin
aminotransferaz (ALT, AST),
Increased total bilirubin
kisline10
increased total bilirubin, neutropaenia, hypermagnesaemia, hypernatraemia, weight decreased
zvišanje vrednosti skupnega bilirubina, nevtropenija, hipermagneziemija, hipernatriemija, zmanjšanje telesne mase
increased total bilirubin,b decreased absolute neutrophil count,b hypermagnesaemia,b, hypernatraemiab
zvišanje vrednosti skupnega bilirubinab, zmanjšanje absolutnega števila nevtrofilcevb, hipermagneziemijab, hipernatriemijab
Increased total blood cholesterol levels.
glavoboli; zvišana raven skupnega holesterola v krvi.
increased total cholesterol (fasted) increased LDL cholesterol (fasted)
zvečana celokupna koncentracija holesterola (na tešče) zvečana celokupna koncentracija LDL (na tešče)
increased total cholesterol (fasted)2, increased LDL-cholesterol (fasted)2, hypophosphataemia3, 5
zvišanje skupnega holesterola (na tešče)2, zvišanje holesterola LDL (na tešče)2, hipofosfatemija3, 5
increased transaminases
povišane transaminaze
increased transaminases
povišanje transaminaz
increased transaminases
zvečana koncentracija aminotransferaz
increased transaminases (AST and/or ALT)1, 2, 3
zvišanje transaminaz (AST in/ali ALT)1, 2, 3
Increased transaminases were reported in 24.2% of patients in clinical studies.
V kliničnih študijah so zvišanje transaminaz zabeležili pri 24,2 % bolnikov.
Increased triglycerides
povečanje trigliceridov
increased triglycerides (fatty acids), bile or sugar in the blood liver and pancreas problems
povišani trigliceridi (maščobne kisline), bilirubin (žolčno barvilo) ali sladkor v krvi težave z jetri in trebušno slinavko
increased triglycerides (fatty acids), bile or sugar in the blood, liver and pancreas problems.
povišani trigliceridi (maščobne kisline), bilirubin (žolčno barvilo) ali sladkor v krvi, težave z jetri in pankreasom.
Increased TSH values (>5.5 µIU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) in the long term open label extension studies.
V dolgoročnih odprtih podaljšanih študijah so pri bolnikih, ki so bili na dolgotrajnem zdravljenju s febuksostatom (5,0 %), opazili povišane vrednosti TSH ( > 5,0 µi.e./ml).
Increased uptake has been identified in extracerebral structures such as salivary glands, skin, muscles and bone in some cases (see section 5.2).
V nekaterih primerih so opazili povečan privzem v zunajmožganske strukture, kot so žleze slinavke, koža, mišice in kosti (glejte poglavje 5.2).
increased uric acid in the blood
povečana sečna kislina v krvi
increased uric acid in the blood;
povečana sečna kislina v krvi;
Increased urination1, 2
pogostejše uriniranje1, 2
Increased urinationa
pogostejše uriniranjea
Increased urine production during night time
zvečana tvorba urina ponoči,
Increased uterine bleeding4
podaljšano krvavenje iz nožnice4
increased warmth in the affected leg
večja toplota v prizadeti nogi,
increased warmth in the affected leg;
povečan občutek toplote v prizadeti nogi
increased weight
povečana telesna masa,
Increased weight
povečanje telesne mase
Increased weight, decreased appetite, increased appetite
povečanje telesne mase, zmanjšan apetit, povečan apetit
increased weight, increased appetite
zvečanje telesne mase, povečanje apetita
increased weight, increased appetite
zvečanje telesne mase, povečanje apetita.
increased weight, nausea, diarrhoea, elevated levels of some liver enzymes
zvečana telesna masa, navzea, driska, zvišana raven nekaterih jetrnih encimov
increased when co-administered with
jih sočasno dajemo z zdravilom
increased when diltiazem is co-
izpostavljenost diltiazemu in
increased white blood cells
povečano število belih krvnih celic
increased white blood cells
zvišanje vrednosti belih krvnih celic
increased yawning
pogostejše zehanje
increased yawning
več zehanja
increased yawning lack of appetite, weight loss
več zehanja zmanjšanje apetita, zmanjšanje telesne mase
increased yawning;
več zehanja;
increased ‘bilirubin’ levels in your blood (bilirubin is a pigment made by the liver)*
zvečana koncentracija bilirubina v krvi (bilirubin je barvilo, ki nastaja v jetrih)
increased,
konjunktivitis,
increased, blood TSH
zvišanje vrednosti kreatinin- fosfokinaze v krvi
increased, creatinine increased
zvišana γ- GT, zvišan kreatinin
increased.
povečana.
increased/decreased sensitivity to stimuli to senses
povečana/zmanjšana občutljivost na dražljaje za čutila
increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture. reduces bone resorption by decreasing osteoclast differentiation and resorbing activity.
povečuje tvorjenje kosti v kulturah kostnega tkiva in replikacijo prekurzorjev osteoblastov ter sintezo kolagena v kulturah kostnih celic; zmanjšuje resorpcijo kosti z zmanjševanjem diferenciacije osteoklastov in resorpcijske dejavnosti.
Increases in ALT levels above baseline have been observed in patients treated with Pegasys, including patients with a viral response.
Pri zdravljenju z zdravilom Pegasys so opazili zvečanje koncentracij ALT glede na izhodiščne vrednosti tudi pri bolnikih z virološkim odzivom.
Increases in AST were less frequently (< 1%) reported.
O zvišanju koncentracije AST so poročali manj pogosto (< 1%).
Increases in AUC were more than dose-proportional and clearance (CL) decreased with increasing dose.
Povečevanje AUC je bilo večje od sorazmernega z višino odmerka, očistek zdravila pa se je z velikostjo odmerka zmanjševal.
Increases in blood creatinine levels (a sign of kidney problems, which might lead less frequent urination).
Zvišanje koncentracije kreatinina v krvi (znak ledvičnih težav, katerih posledica je lahko manjša pogostost uriniranja).
Increases in blood glucose levels have been reported with Tasigna therapy (see section 4.4).
Pri zdravljenju z zdravilom Tasigna so poročali o zvišanih vrednostih glukoze v krvi (glejte poglavje 4.4).
Increases in blood levels of liver enzymes.
Zvišanje koncentracije jetrnih encimov v krvi.
Increases in blood sugar or cholesterol (a type of blood fat)
Povečane vrednosti krvnega sladkorja.
Increases in BMD at the total hip were 0.3, 1.9, and 3.0 for the 3 groups, respectively.
Povečki BMD celotnega kolka so bili 1,9% v prvi omenjeni skupini, 0,3% v drugi omenjeni skupini in 2,8% v zadnji omenjeni skupini.
increases in body temperature (fever)
zvišana telesna temperatura (vročina)
Increases in bupropion dosage
Odmerek bupropiona je treba
Increases in cholesterol and triglycerides
zvišane vrednosti holesterola in trigliceridov
Increases in cholesterol and triglyceridesh
zvišane vrednosti holesterola in trigliceridovh
Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6–mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 – 1.0 mg/kg/day.
V perifernih limfocitih bolnikov z levkemijo, pri bolnikih s karcinomom ledvičnih celic, ki so prejemali nedoločen odmerek 6-merkaptopurina, in pri bolnikih s kronično boleznijo ledvic, ki so bili zdravljeni z odmerkom 0,4–1,0 mg/kg/dan, je bilo opaženo večje število kromosomskih aberacij.
increases in concentrations of these
ANTIKONVULZIVI
increases in creatinine in the blood
povišano raven kreatinina v krvi;
Increases in enzymes produced by the liver called transaminases, increases of an enzyme produced by the pancreas called amylase
Povečana aktivnost jetrnih encimov (transaminaze) in povečana aktivnost encima trebušne slinavke (amilaza).
Increases in enzymes produced by the liver called transaminases, increases of an enzyme produced by the pancreas called lipase.
Zvišana aktivnost jetrnih encimov, imenovanih transaminaze, zvišana aktivnost encima trebušne slinavke, imenovanega lipaza.
Increases in ferritin and transferrin saturation (TSAT) are observed with Fexeric use.
Pri uporabi zdravila Fexeric so opazili povečanje vrednosti feritina in saturacije transferina (TSAT- transferrin saturation).
Increases in haemoglobin or haematocrit, reflective of increases in red blood cell mass, may occur during treatment with axitinib (see section 4.8, polycythaemia).
Med zdravljenjem z aksitinibom lahko pride do zvišanj ravni hemoglobina ali hematokrita, kar je posledica povečanja mase rdečih krvničk (glejte poglavje 4.8, policitemija).
Increases in IOP (7 mmHg from baseline) were more frequent in subjects treated with fluticasone furoate 110 micrograms: 7 (2%) for fluticasone furoate 110 micrograms once daily and 1 (<1%) for placebo.
7 mmHg od izhodišča) je bilo pogostejše pri preiskovancih, zdravljenih s 110 mikrogrami flutikazonfuroata: 7 (2 %) s 110 mikrogrami flutikazonfuroata enkrat na dan in 1 (< 1 %) s placebom.
Increases in lipase activities were transient and were generally not accompanied by signs or symptoms of pancreatitis in subjects with various solid tumours.
Zvečanje aktivnosti lipaze je bilo prehodno in ga pri preskušancih z različnimi čvrstimi tumorji praviloma niso spremljali znaki ali simptomi pankreatitisa.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon.
Manj pogosto je bila povečana aktivnost jetrnih encimov v povezavi s kliničnimi znaki anoreksije, apatije ali bruhanja.
Increases in liver enzyme activities associated with symptoms of anorexia, apathy or vomiting were uncommon.
Manj pogosto je bila povečana aktivnost jetrnih encimov v povezavi s kliničnimi znaki anoreksije, apatije ali bruhanja.
Increases in liver enzymes (alanine aminotransferase or aspartate aminotransferase) in laboratory blood tests
zvišana raven jetrnih encimov (alanin-aminotransferaze ali aspartat-aminotransferaze) pri laboratorijskih krvnih preiskavah,
Increases in liver enzymes (identified in routine liver function testing)
zvišanje jetrnih encimov (ugotovljeno pri rutinskem testiranju jetrne funkcije);
increases in liver enzymes in the blood (these will show up in blood tests)
povečana raven jetrnih encimov v krvi (to pokažejo krvne preiskave)
Increases in liver enzymes were reported in studies with nitrocatechol inhibitors of catechol-O- methyltransferase (COMT).
V študijah z nitrokateholnimi zaviralci katehol-O-metil transferaze (COMT) so poročali o zvišanju ravni jetrnih encimov.
increases in liver enzymes*
zvišanje jetrnih encimov
Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)
zvišana raven jetrnih encimov, hiperbilirubinemija (zvišana raven žolčnega barvila v krvi)
increases in MCV, decreases in neutrophils
zvišanje MCV, zmanjšanje števila nevtrofilcev
Increases in mean systolic and diastolic blood pressure, of approximately 3 mmHg and 1 mmHg respectively, above original baseline were observed upon discontinuation of Intuniv.
Po ukinitvi zdravila Intuniv so opazili zvišanje povprečnega sistoličnega in diastoličnega tlaka za 3 mm Hg oziroma 1 mm Hg nad izhodiščne vrednosti.
Increases in mirabegron exposure due to drug-drug interactions may be associated with increases in pulse rate.
Večjo izpostavljenost mirabegronu, nastalo zaradi medsebojnega delovanja zdravil, lahko spremlja zvišana srčna frekvenca.
Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with Cubicin (see also sections 4.5, 4.8 and 5.3).
Med zdravljenjem z zdravilom Cubicin so poročali o zvišanju ravni kreatin-fosfokinaze v plazmi (CPK; MM izoencim), povezane z bolečinami v mišicah in/ali s slabotnostjo in o primerih miozitisa, mioglobinemije in rabdomiolize (glejte poglavja 4.5, 4.8 in 5.3).
Increases in plasma exposure to bedaquiline would be expected when it is co-administered with other ritonavir-boosted HIV protease inhibitors.
Pri sočasni uporabi z drugimi z ritonavirjem okrepljenimi zaviralci HIV proteaze je pričakovati zvečanje plazemske izpostavljenosti bedakilinu.
Increases in postimplantation loss, reduced foetal body weights and decreased litter sizes together with increases in the number of malformations (gross external, soft tissue) and skeletal alterations (including retarded ossification) were reported in rats receiving doses which produced approximately 2 to 3 fold the clinical exposure (54 mg/m2/day) and in rabbits receiving 12 mg/m2/day clofarabine. (There are no exposure data in rabbits.) The threshold for developmental toxicity was considered to be 6 mg/m2/day in rats and 1.2 mg/m2/day in rabbits.
Pri podganah, ki so prejemale odmerke, ki so bili približno 2- do 3-krat večji od klinične izpostavljenosti (54 mg/m2/dan), ter pri kuncih, ki so prejemali 12 mg klofarabina/m2/dan, so poročali o povečanju postimplantacijske izgube, zmanjšanju telesne mase ploda in zmanjšanju velikosti mladičev, skupaj s povečanjem števila malformacij (zunanje, mehka tkiva) ter spremembami na skeletu (vključno z zaostalo osifikacijo). (Za kunce ni podatkov o izpostavljenosti.) Odmerek, pri katerem je prišlo do razvojne toksičnosti, je bil 6 mg/m2/dan pri podganah in 1,2 mg/m2/dan pri kuncih.
Increases in serum creatinine occurred within the first week of treatment with dolutegravir and remained stable through 48 weeks.
Zvišane vrednosti serumskega kreatinina so se pojavile v prvem tednu zdravljenja z dolutegravirjem in ostale nespremenjene skozi 48 tednov.
Increases in the blood of a substance called bilirubin
Povečane vrednosti bilirubina v krvi.
Increases in the QTc interval to over 500 msec occurred in 0.5%, and changes from baseline in excess of 60 msec occurred in 1.1% of the 450 solid tumour patients; both of these parameters are recognized as potentially significant changes.
Podaljšanje intervala QTc prek 500 milisekund se je pojavilo pri 0,5 %, spremembe od izhodišča, večje od 60 milisekund, pa pri 1,1 % od 450 bolnikov s čvrstimi tumorji; oba parametra veljata za potencialno pomembni spremembi.
Increases in total serum cholesterol levels have been reported with Tasigna therapy (see section 4.4).
Pri zdravljenju z zdravilom Tasigna so poročali o zvišanih vrednostih celokupnega holesterola v serumu (glejte poglavje 4.4).
Increases in triglycerides (a type of blood fat), changes in body shape because of fat redistribution,
Povečane vrednosti trigliceridov (vrsta maščobe) v krvi, spremembe telesne oblike zaradi spremembe v porazdelitvi telesnega maščevja.
Increases in triglycerides (a type of blood fat).
Zvišana vrednost trigliceridov (vrsta maščobe v krvi).
Increases in uric acid level (0.7 mg/dl at 12 weeks and 0.5 mg/dl at 24 weeks) were observed after Ilaris treatment in comparative trials in gouty arthritis.
V primerjalnih preskušanjih pri bolnikih z uričnim artritisom so po zdravljenju z zdravilom Ilaris opažali zvišanje koncentracije sečne kisline (za 0,7 mg/dl po 12 tednih in za 0,5 mg/dl po 24 tednih).
Increases in volume, measured radiographically occurred early during filgrastim therapy and tended to plateau.
Radiografsko izmerjeno povečanje vranice se je pojavilo zgodaj med zdravljenjem s filgrastimom in se je nagibalo k doseganju platoja.
Increases in volume, measured radiographically, occurred early during filgrastim therapy and tended to plateau.
Povečanje volumna, ki ga merimo radiografsko, se je pojavilo zgodaj v poteku zdravljenja s filgrastimom in je pozneje doseglo plato.
Increases in volume, measured radiographically, occurred early during filgrastim therapy and tended to plateau.
Radiografsko izmerjeno povečanje vranice se je pojavilo zgodaj med zdravljenjem s filgrastimom in se je nagibalo k doseganju platoja.
Increases in your blood sugar level (diabetes)
zvišanje ravni krvnega sladkorja (sladkorna bolezen);
increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
povečuje lipogenezo v jetrih in maščobnem tkivu ter zavira lipolizo,
increases lipogenesis in the liver and adipose tissue and inhibits lipolysis,
zvečuje lipogenezo v jetrih in maščevju in zavira lipolizo,
Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance.
Približno 10% povečanje QT intervala ECG so opazili v raziskavi na zdravih psih beaglih, ki so jim aplicirali 8 mg/kg, vendar pa naj tako povečanje ne bi imelo kliničnega pomena.
Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT) occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily.
Povišanje alanin-aminotransferaze (ALT) do več kot trikratne zgornje referenčne vrednosti (ULN), se je pojavilo pri 1 % bolnikov, ki so prejemali zdravilo Tasmar 100 mg trikrat na dan in pri 3 % bolnikov, ki so prejemali zdravilo Tasmar 200 mg trikrat na dan.
Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT)occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily.
Povišanje alanin-aminotransferaze (ALT) do več kot trikratne zgornje referenčne vrednosti (ULN), se je pojavilo pri 1 % bolnikov, ki so prejemali zdravilo Tasmar 100 mg trikrat na dan in pri 3 % bolnikov, ki so prejemali zdravilo Tasmar 200 mg trikrat na dan.
Increases were approximately two times more likely in females.
Povišanja so bila približno dvakrat verjetnejša pri ženskah.
Increasing age
Starost
Increasing age may increase haemorrhagic risk (see section 5.2).
S starostjo se tveganje za krvavitve lahko poveča (glejte poglavje 5.2).
Increasing baseline darunavir fold change in EC50 (FC) was associated with decreasing virologic response.
Povečevanje stopnje spremembe (FC – fold change) izhodiščne vrednosti EC50 je bila povezana z zmanjšanim virološkim odzivom.
Increasing exposure (AUC) in patients with moderate and severe renal impairment during studies was observed.
Med študijami so pri bolnikih z zmerno in hudo okvaro ledvic opazili povečanje izpostavljenosti (AUC).